|Bid||0.5737 x 1000|
|Ask||0.9500 x 10000|
|Day's Range||0.7805 - 0.8300|
|52 Week Range||0.7600 - 1.4700|
|PE Ratio (TTM)||2.57|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.15|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis VIVUS, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 11.23 million, Net Earnings of USD -13.39 million. Gross margins narrowed from 80.79% to 68.20% compared to the same period last year, operating (EBITDA) margins now -42.20% from -24.58%. Change in operating cash ... Read more (Read more...)
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
NEW YORK, NY / ACCESSWIRE / September 8, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.
VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced ...
VIVUS, Inc. and Alvogen Malta Operations Ltd, today announced an agreement under which Alvogen will market Qsymia® in the Republic of Korea for the treatment of chronic weight...
VIVUS (VVUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
VIVUS, Inc. announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories, Inc. resolving patent litigation related to Qsymia® (phentermine ...
VIVUS,Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced ...
NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported ...
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
VIVUS, Inc. announced today that it has entered into a settlement agreement with Actavis Laboratories FL resolving patent litigation related to Qsymia® capsules CIV. The litigation, which has been pending ...
BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).
Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.
Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.
Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.
Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.
KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.
Neothetics, Inc. (NEOT) announced disappointing top line results from a phase II proof-of-concept study, LIPO-202-CL-31, evaluating its lead candidate, LIPO-202, for reduction of submental subcutaneous fat.
Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.
Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.